Affinage

BCL2

Apoptosis regulator Bcl-2 · UniProt P10415

Length
239 aa
Mass
26.3 kDa
Annotated
2026-06-09
100 papers in source corpus 23 papers cited in narrative 22 extracted findings
Cross-family judge vs UniProt: Affinage preferred faithfulness: 7/7 claims corpus-supported (100%)

Mechanistic narrative

Synthesis pass · prose summary of the discoveries below

BCL-2 is the prototypical anti-apoptotic regulator of programmed cell death, an integral outer mitochondrial membrane protein oriented toward the cytosol that also resides at the nuclear envelope and endoplasmic reticulum (PMID:1453000, PMID:8381212, PMID:9714773). It suppresses apoptosis by preventing mitochondrial permeability transition and the release of apoptogenic factors such as cytochrome c, and it acts downstream of upstream death signals including ceramide while remaining capable of blocking even caspase-independent death (PMID:9714773, PMID:8643573, PMID:9852091). Structurally, BCL-2 folds into six alpha-helices presenting a surface hydrophobic groove whose subtle features tune its affinity for BH3-domain peptides of pro-apoptotic proteins such as BAD and BAK, while its α5–α6 helices form ion-conductive membrane channels that are necessary but not sufficient for cytoprotection (PMID:9812996, PMID:10200486, PMID:11248023). Genetic epistasis established that BCL-2 and BAX each regulate apoptosis independently, so that BCL-2 represses death even without BAX and BCL-2:BAX heterodimerization alone does not account for its activity (PMID:9115213, PMID:9241272). BCL-2 activity is set post-translationally: phosphorylation at serine 70 is required for full anti-apoptotic function, while ARTS-bridged, XIAP-mediated ubiquitylation at lysine 17 targets BCL-2 for degradation (PMID:9115213, PMID:29020630). Beyond mitochondrial gatekeeping, BCL-2 controls intracellular Ca2+ by lowering ER store filling and by binding and inhibiting ryanodine receptors through its BH4 domain (PMID:12543100, PMID:24762814), regulates autophagy by sequestering AMBRA1 and competing for BECLIN 1 (PMID:21358617), and is transcriptionally controlled by opposing inputs from NF-κB2/p52–Bcl-3 (activating) and c-Myc/E2F-1 (repressing) (PMID:12835724, PMID:11704823). Non-canonical roles include promotion of cell migration/invasion via MMP-2 activation and cell-cycle modulation through suppression of p21 and p16 (PMID:9872414, PMID:11983915).

Mechanistic history

Synthesis pass · year-by-year structured walk · 19 steps
  1. 1992 High

    Resolved where BCL-2 acts in the cell, placing it at the outer mitochondrial membrane rather than the inner membrane, which reframed its mechanism around the mitochondrial surface.

    Evidence Immunoelectron microscopy by three independent preparation methods plus confocal microscopy

    PMID:1453000

    Open questions at the time
    • Does not establish how BCL-2 is targeted/anchored to the membrane
    • Functional consequence of perinuclear/cytoplasmic pools left open
  2. 1993 High

    Showed BCL-2 protection is independent of a functional respiratory chain, decoupling its anti-apoptotic function from mitochondrial bioenergetics and pointing to a structural/signaling role across multiple membranes.

    Evidence Apoptosis assays in mtDNA-deficient cells with BCL-2 overexpression; fractionation

    PMID:8381212

    Open questions at the time
    • Mechanism at ER/nuclear envelope not defined
    • Does not identify the protective biochemical step
  3. 1994 Medium

    Connected BCL-2 to the p53 tumor-suppressor axis, showing it diverts p53 output from apoptosis toward growth arrest without altering p53 levels or nuclear localization.

    Evidence Temperature-sensitive p53 system with transformation, cell-cycle, and localization readouts

    PMID:8139558

    Open questions at the time
    • Direct molecular link to p53 machinery not defined
    • Single inducible system
  4. 1997 High

    Established that phosphorylation at S70 is a required regulatory switch for full anti-apoptotic activity and that BAX heterodimerization alone is insufficient, separating dimerization from death-suppression.

    Evidence S70A/S70E mutagenesis with survival assays and co-IP for BAX binding

    PMID:9115213

    Open questions at the time
    • Kinase responsible for S70 phosphorylation not identified here
    • Structural effect of phosphorylation unknown
  5. 1997 High

    Genetic epistasis in mice proved BCL-2 and BAX act independently in vivo, refining the model away from simple obligate heterodimer titration.

    Evidence Bcl-2, Bax single- and double-knockout mice with thymic/lymphocyte phenotypes

    PMID:9241272

    Open questions at the time
    • Does not define the BAX-independent effector mechanism
    • Tissue-specific differences not fully resolved
  6. 1996 Medium

    Placed BCL-2 downstream of ceramide signaling but upstream of execution, defining its position in the death pathway by epistasis.

    Evidence BCL-2 overexpression with ceramide measurement, Rb activation, and apoptosis readouts

    PMID:8643573

    Open questions at the time
    • No direct ceramide-effector identified
    • Single lab
  7. 1997 Medium

    Extended the p53 connection by showing BCL-2 blocks genotoxin-induced apoptosis through inhibiting nuclear import of induced p53.

    Evidence Confocal imaging and nuclear/cytoplasmic fractionation under DNA damage

    PMID:9419967

    Open questions at the time
    • Mechanism of trafficking inhibition unknown
    • Reconciliation with prior p53-level data incomplete
  8. 1998 High

    Defined a biophysical effector activity: BCL-2 forms ion-conductive channels via α5–α6, helices that are necessary but not sufficient for survival, linking structure to function.

    Evidence Artificial-membrane channel assays plus α5–α6 deletion/swap rescue in human cells and yeast

    PMID:10200486 PMID:9812996

    Open questions at the time
    • Physiological channel substrate/conductance in vivo unproven
    • What else besides channel activity is required not defined here
  9. 1998 Medium

    Established BCL-2 prevents mitochondrial permeability transition and cytochrome c release, the central mitochondrial mechanism of its protection.

    Evidence Fractionation, permeability transition assays, and cytochrome c release assays (review synthesis)

    PMID:9714773

    Open questions at the time
    • Review-level synthesis rather than single primary dataset
    • Direct molecular gating mechanism not resolved
  10. 1998 Medium

    Showed protection extends to caspase-independent death, broadening BCL-2's mechanism beyond blocking caspase activation.

    Evidence NO-induced death with caspase inhibitors/p35 in PC12 and HeLa cells

    PMID:9852091

    Open questions at the time
    • Effector of caspase-independent protection unidentified
    • Single lab
  11. 2001 High

    Provided the structural basis for selective anti-apoptotic activity, showing a six-helix fold with a hydrophobic groove whose features dictate BH3-peptide binding affinity.

    Evidence NMR of a BCL-2/BCL-xL chimera with BAD/BAK BH3 peptide binding

    PMID:11248023

    Open questions at the time
    • Chimeric construct rather than native BCL-2
    • Full-length membrane-embedded structure not solved
  12. 2002 Medium

    Identified ER Ca2+ regulation as an anti-apoptotic mechanism, showing BCL-2 lowers ER store filling to reduce apoptotic sensitivity.

    Evidence ER Ca2+ store measurements with apoptosis assays in BCL-2-overexpressing cells

    PMID:12543100

    Open questions at the time
    • Molecular target lowering ER Ca2+ not identified here
    • Single lab
  13. 2002 Medium

    Clarified mitochondrial biophysics, showing BCL-2 alters mitochondrial volume/complexity without changing membrane potential, correcting dye-based misinterpretations.

    Evidence Calibrated respiration, potential, and particle-sizing measurements in permeabilized cells

    PMID:12207028

    Open questions at the time
    • Functional consequence of volume change unresolved
    • Single lab
  14. 2002 Medium

    Revealed a non-apoptotic proliferative role, with BCL-2 promoting myocyte proliferation via suppression of p21/p16 and altered Mdm2-p53 complexes.

    Evidence Cardiac-specific BCL-2 transgenic mice with proliferation and cell-cycle-inhibitor readouts

    PMID:11983915

    Open questions at the time
    • Direct link between BCL-2 and cell-cycle inhibitor regulation unknown
    • Tissue-specific
  15. 2003 Medium

    Defined transcriptional activation of BCL-2 by NF-κB2/p52–Bcl-3 through a defined κB promoter site.

    Evidence Promoter-reporter, EMSA, and stable p100/p52 overexpression with endogenous BCL-2 readout

    PMID:12835724

    Open questions at the time
    • Cell-type generality not tested
    • Single lab
  16. 2001 Medium

    Defined transcriptional repression of BCL-2 by c-Myc and E2F-1, with BCL-2 loss mediating accelerated apoptosis, and rescue confirming causality.

    Evidence c-Myc/E2F-1 overexpression and DNA-binding mutants with BCL-2 restoration in IL-3 deprivation

    PMID:11704823

    Open questions at the time
    • Direct vs indirect promoter action not fully resolved
    • Single lab
  17. 2011 Medium

    Linked BCL-2 to autophagy control, showing mitochondrial BCL-2 sequesters AMBRA1 and competes for BECLIN 1, releasing AMBRA1 upon autophagy induction.

    Evidence Reciprocal co-IP, fractionation, and autophagy assays with compartment-specific BCL-2 constructs

    PMID:21358617

    Open questions at the time
    • Signal triggering AMBRA1 release not defined
    • Single lab
  18. 2014 High

    Established a BH4-domain Ca2+ control mechanism, with BCL-2 directly binding and inhibiting ryanodine receptors to dampen Ca2+ release.

    Evidence Co-IP (ectopic and endogenous), pulldown, SPR, and Ca2+ imaging in HEK293 and hippocampal neurons

    PMID:24762814

    Open questions at the time
    • Structural basis of BH4-RyR contact not solved
    • In vivo physiological role in neurons not established
  19. 2017 High

    Defined the degradation pathway for BCL-2, with ARTS bridging XIAP to ubiquitylate K17 and a K17A mutant gaining stability and anti-apoptotic potency.

    Evidence Ternary-complex co-IP, K17A mutagenesis, mass spectrometry, and XIAP/ARTS-knockout MEFs

    PMID:29020630

    Open questions at the time
    • Signals controlling ARTS/XIAP engagement not defined
    • Deubiquitylase counterpart not identified

Open questions

Synthesis pass · forward-looking unresolved questions
  • How BCL-2's multiple effector activities — channel formation, BH3 sequestration, ER/RyR Ca2+ control, and autophagy regulation — are integrated and prioritized within a single cell remains unresolved.
  • No unified structural model of membrane-embedded full-length BCL-2 with bound partners
  • Kinase for S70 not identified in this corpus
  • Quantitative hierarchy among mitochondrial vs ER functions unknown

Mechanism profile

Synthesis pass · controlled-vocabulary classification · explore literature graph →
Molecular activity
GO:0140313 molecular sequestering activity 4 GO:0060089 molecular transducer activity 2 GO:0098772 molecular function regulator activity 2 GO:0005215 transporter activity 1
Localization
GO:0005739 mitochondrion 4 GO:0005783 endoplasmic reticulum 3 GO:0005635 nuclear envelope 2 GO:0005829 cytosol 1
Pathway
R-HSA-5357801 Programmed Cell Death 4 R-HSA-392499 Metabolism of proteins 2 R-HSA-74160 Gene expression (Transcription) 2 R-HSA-9612973 Autophagy 1
Partners
AMBRA1ARTSBADBAKBAXBECLIN1RYRXIAP

Evidence

Reading pass · 22 per-paper findings extracted from the source corpus
Year Finding Method Journal Conf PMIDs
1992 BCL-2 protein localizes to the outer mitochondrial membrane (not inner membrane as previously suggested), as well as to the perinuclear membrane and throughout the cytoplasm, as determined by immunoelectron microscopy using three independent sample preparation methods. Immunoelectron microscopy (progressive lowering of temperature, cryosectioning, freeze-substitution) and confocal microscopy The journal of histochemistry and cytochemistry High 1453000
1993 BCL-2-mediated protection from apoptosis does not require mitochondrial respiration, as BCL-2 overexpression protects cells lacking mitochondrial DNA (and thus lacking a functional respiratory chain) from apoptosis. BCL-2 protein in overexpressing cells is associated with the nuclear envelope and endoplasmic reticulum as well as with mitochondria. Apoptosis assays in mtDNA-deficient cell lines with BCL-2 overexpression; subcellular fractionation and localization Nature High 8381212
1997 Phosphorylation of BCL-2 at serine 70 (S70) is required for its full anti-apoptotic function. An S70A mutation abolishes phosphorylation and impairs cell survival upon IL-3 deprivation or etoposide treatment, whereas a phosphomimetic S70E mutant more potently suppresses apoptosis. Importantly, the S70A loss-of-function mutant retains the ability to heterodimerize with BAX, demonstrating that BCL-2:BAX heterodimerization alone is not sufficient for BCL-2 death-suppressor activity. Site-directed mutagenesis (serine-to-alanine and serine-to-glutamate mutations), cell survival assays, IL-3 deprivation, etoposide treatment, co-immunoprecipitation for heterodimerization The Journal of biological chemistry High 9115213
1997 BCL-2 and BAX each independently regulate apoptosis in vivo. Genetic epistasis using Bcl-2 knockout, Bax knockout, and double-knockout mice showed that BCL-2 overexpression represses apoptosis even in the absence of BAX, while a single copy of BAX promotes apoptosis without BCL-2. Genetic epistasis using gain- and loss-of-function mouse models (Bcl-2-deficient, Bax-deficient, and double-deficient mice); thymic apoptosis and lymphocyte development phenotype analysis Nature genetics High 9241272
1998 BCL-2 family proteins (BCL-2, BCL-XL, BAX) form ion-conductive pores in artificial membranes, suggesting a channel-forming mechanism. The pore-forming fifth and sixth alpha-helices (α5-α6) of BCL-2 are necessary but not sufficient for its cytoprotective function; deletion or swapping of α5-α6 abolishes BCL-2-mediated cell survival in human cells and yeast. In vitro channel activity assays in artificial membranes; deletion mutagenesis of α5-α6 helices; apoptosis rescue assays in human cells and yeast Saccharomyces cerevisiae The Journal of biological chemistry / Cell death and differentiation High 10200486 9812996
1998 BCL-2 resides in the outer mitochondrial membrane oriented toward the cytosol and prevents mitochondrial permeability transition pore opening and release of apoptogenic proteins (e.g., cytochrome c) from mitochondria. Subcellular fractionation; mitochondrial permeability transition assays; cytochrome c release assays Biochimica et biophysica acta Medium 9714773
2001 The solution structure of BCL-2 (determined as a BCL-2/BCL-xL chimera) consists of 6 alpha-helices with a hydrophobic groove on the surface similar to BCL-xL. Structural comparison revealed subtle differences in the hydrophobic binding groove between BCL-2 isoforms that correlate with differences in binding affinity for BH3-domain peptides from BAD and BAK, and thus differences in anti-apoptotic activity. NMR spectroscopy; peptide binding assays with BH3 domain peptides from BAD and BAK Proceedings of the National Academy of Sciences of the United States of America High 11248023
1994 BCL-2 blocks p53-mediated apoptosis and diverts p53 activity from apoptosis induction to growth arrest. BCL-2 does not affect p53 nuclear localization or protein levels in this context. Temperature-sensitive p53 mutant system; transformation assays; cell cycle analysis; immunofluorescence for p53 localization; Western blot for p53 levels Molecular and cellular biology Medium 8139558
1997 BCL-2 suppresses p53-induced apoptosis following genotoxic damage by inhibiting nuclear import of induced wild-type p53 protein, as shown by confocal microscopy and immunoblotting of nuclear/cytoplasmic fractions. Confocal microscopy; subcellular fractionation/immunoblotting; genotoxic stress (DNA damage) assays Oncogene Medium 9419967
1996 BCL-2 acts downstream of ceramide in the cell death pathway. Overexpression of BCL-2 prevents ceramide-induced apoptosis but does not interfere with ceramide formation or ceramide-induced cell cycle arrest (retinoblastoma protein activation), placing BCL-2 function downstream of ceramide signaling but upstream of the apoptosis execution step. BCL-2 overexpression; ceramide measurement; cell death assays; cell cycle analysis; lipid second messenger pathway dissection Proceedings of the National Academy of Sciences of the United States of America Medium 8643573
1998 BCL-2 can prevent caspase-independent cell death (NO-induced death with chromatin condensation, nuclear compaction, and mitochondrial swelling, without caspase activation), establishing that BCL-2's protective mechanism extends beyond inhibition of caspase activation. NO-induced cell death assays; peptide caspase inhibitors; p35 expression; Bax expression; BCL-2 overexpression in PC12 and HeLa cells The Journal of biological chemistry Medium 9852091
2002 BCL-2 overexpression increases mitochondrial volume and structural complexity without changing mitochondrial membrane potential, delta pH, or intramitochondrial K+ concentration, contrary to prior interpretations based on fluorometric dye uptake. Calibrated mitochondrial respiration measurements; membrane potential measurements (calibrated); flow cytometry particle sizing and light scattering; digitonin-permeabilized cells The Journal of biological chemistry Medium 12207028
2002 BCL-2 directly reduces the filling state of the endoplasmic reticulum Ca2+ store, and this reduction in ER Ca2+ content renders cells less sensitive to apoptotic stimuli, identifying a Ca2+ signaling mechanism for BCL-2's anti-apoptotic function. ER Ca2+ store measurements; apoptosis assays; BCL-2 overexpression in cell lines Cell calcium Medium 12543100
2011 BCL-2 at the mitochondria (mito-BCL-2) binds AMBRA1 under basal conditions. Upon autophagy induction, AMBRA1 is released from mito-BCL-2 and is recruited to BECLIN 1, promoting BECLIN 1-dependent autophagy. AMBRA1 can compete with both mitochondrial and ER-resident BCL-2 to bind BECLIN 1. Co-immunoprecipitation; subcellular fractionation; autophagy induction assays; overexpression and knockdown of AMBRA1, BCL-2, BECLIN 1 The EMBO journal Medium 21358617
2014 BCL-2 directly binds and inhibits ryanodine receptors (RyRs) via its BH4 domain. BCL-2 co-immunoprecipitates with RyRs in ectopic expression systems and in native rat hippocampi; purified RyR domains interact with BCL-2's BH4 domain in pulldown and surface plasmon resonance experiments. Expression of full-length BCL-2 or electroporation of the BH4 domain peptide dampens RyR-mediated Ca2+ release in HEK293 cells and hippocampal neurons. Co-immunoprecipitation (ectopic and endogenous); pulldown with purified RyR domains; surface plasmon resonance (SPR); Ca2+ imaging in HEK293 cells and hippocampal neurons; BH4-domain peptide electroporation Journal of cell science High 24762814
2017 BCL-2 is ubiquitylated and degraded through a ternary complex involving ARTS (Sept4_i2) and XIAP. ARTS binds BCL-2 via its BH3 domain, bringing XIAP into proximity to act as an E3 ubiquitin ligase for BCL-2. Lysine 17 of BCL-2 is the main ubiquitylation acceptor site; a K17A BCL-2 mutant shows increased stability and enhanced anti-apoptotic potency. BCL-2 ubiquitylation is reduced in both XIAP- and Sept4/ARTS-deficient MEFs. Co-immunoprecipitation (ternary complex); site-directed mutagenesis (BH3 domain of BCL-2, K17A mutant); ubiquitylation assays; mass spectrometry; XIAP/ARTS knockout MEFs; apoptosis assays Cell reports High 29020630
2003 NF-κB2/p100 and its processed product p52, in association with Bcl-3, transcriptionally activate the BCL-2 promoter via a κB site at position -180 that is bound only by p50 or p52 homodimers. Stable overexpression of p100/p52 induces endogenous BCL-2 expression in breast cancer cells. BCL-2 promoter-reporter transfection assays; electrophoretic mobility shift assay (EMSA); stable overexpression of p100/p52 in MCF7AZ cells; Western blot for endogenous BCL-2 Leukemia Medium 12835724
2001 c-Myc and E2F-1 suppress BCL-2 protein and mRNA levels in an ARF/p53-independent manner, and this suppression of BCL-2 mediates accelerated apoptosis upon IL-3 deprivation. Restoration of BCL-2 protein levels effectively blocks this accelerated apoptosis. DNA-binding activity of c-Myc and E2F-1 is required for BCL-2 suppression. Overexpression and DNA-binding mutant analysis of c-Myc and E2F-1; BCL-2 restoration by retroviral transduction; RT-PCR and Western blot; IL-3 deprivation apoptosis assay; dominant-negative p53 Oncogene Medium 11704823
1997 BCL-2 overexpression increases telomerase activity in human cancer cells, and IL-2 deprivation-induced down-regulation of BCL-2 causes concurrent inhibition of telomerase activity, establishing a functional link between BCL-2 and telomerase regulation. Stable BCL-2 overexpression; TRAP assay for telomerase activity; IL-2 deprivation in CTLL-2 cells; cell cycle analysis The Journal of biological chemistry Low 9162048
1998 BCL-2 can function as an adapter or docking protein in addition to its ion channel activity, and these dual activities together begin to explain how BCL-2 controls the programmed cell death pathway. Protein interaction/docking assays; channel activity assays in membranes (as reviewed) Histology and histopathology Low 9589906
1998 BCL-2 promotes migration and invasion of glioma cells by activating matrix metalloproteinase-2 (MMP-2) and altering the expression of MMP-2/-3/-12, MMP-9/-12, cell surface urokinase-type plasminogen activator (u-PA), and reducing TIMP-2 expression. Ectopic BCL-2 expression in glioma sublines; spheroid migration assay; Matrigel invasion assay; fetal rat-brain aggregate invasion; zymography for MMP-2 activation; RT-PCR for MMP/TIMP/u-PA mRNA FEBS letters Medium 9872414
2002 BCL-2 overexpression promotes myocyte proliferation in vivo, associated with decreased expression of cell-cycle inhibitors p21(WAF1) and p16(INK4a) and increased Mdm2-p53 complexes, identifying a non-apoptotic role for BCL-2 in cell cycle regulation. Transgenic mice overexpressing BCL-2 under α-myosin heavy chain promoter; BrdU labeling; mitotic index; immunohistochemistry for p21, p16, Mdm2-p53; co-immunoprecipitation of Mdm2-p53 Proceedings of the National Academy of Sciences of the United States of America Medium 11983915

Source papers

Stage 0 corpus · 100 papers · ranked by NIH iCite citations
Year Title Journal Citations PMID
1998 BCL-2 family: regulators of cell death. Annual review of immunology 1428 9597135
2010 The BCL-2 family reunion. Molecular cell 1203 20159550
1998 Bcl-2 family proteins. Oncogene 869 9916985
1993 Bcl-2 blocks apoptosis in cells lacking mitochondrial DNA. Nature 730 8381212
2008 Bcl-2 family proteins and cancer. Oncogene 687 18955968
2015 The mystery of BCL2 family: Bcl-2 proteins and apoptosis: an update. Archives of toxicology 554 25618543
2019 BCL-2 family isoforms in apoptosis and cancer. Cell death & disease 544 30792387
2017 MOMP, cell suicide as a BCL-2 family business. Cell death and differentiation 530 29053143
1997 Bcl-2 phosphorylation required for anti-apoptosis function. The Journal of biological chemistry 512 9115213
2013 Multiple functions of BCL-2 family proteins. Cold Spring Harbor perspectives in biology 511 23378584
1997 Bcl-2 gene family in the nervous system. Annual review of neuroscience 508 9056714
2008 BCL-2 family antagonists for cancer therapy. Nature reviews. Drug discovery 497 19043450
2023 Mechanisms of BCL-2 family proteins in mitochondrial apoptosis. Nature reviews. Molecular cell biology 481 37438560
2017 BCL-2 proteins and apoptosis: Recent insights and unknowns. Biochemical and biophysical research communications 479 28676391
2004 The role of Bcl-2 family members in tumorigenesis. Biochimica et biophysica acta 442 14996506
2018 Targeting BCL-2 regulated apoptosis in cancer. Open biology 390 29769323
1994 Bcl-2 blocks p53-dependent apoptosis. Molecular and cellular biology 372 8139558
2003 Regulation of apoptosis by Bcl-2 family proteins. Journal of cellular and molecular medicine 365 14594549
2001 Solution structure of the antiapoptotic protein bcl-2. Proceedings of the National Academy of Sciences of the United States of America 360 11248023
1992 Ultrastructural localization of bcl-2 protein. The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society 357 1453000
1997 Bcl-2 and Bax function independently to regulate cell death. Nature genetics 353 9241272
2014 Many players in BCL-2 family affairs. Trends in biochemical sciences 341 24503222
1998 Bcl-2 family proteins and mitochondria. Biochimica et biophysica acta 319 9714773
2019 Mitochondrial Reprogramming Underlies Resistance to BCL-2 Inhibition in Lymphoid Malignancies. Cancer cell 303 31543463
1996 Bcl-2 interrupts the ceramide-mediated pathway of cell death. Proceedings of the National Academy of Sciences of the United States of America 289 8643573
2019 Beclin 1, Bcl-2 and Autophagy. Advances in experimental medicine and biology 257 31776982
1996 bcl-2: role in epithelial differentiation and oncogenesis. Human pathology 256 8617450
1998 Bcl-2 family proteins as ion-channels. Cell death and differentiation 245 10200486
1992 Bcl-2: a repressor of lymphocyte death. Immunology today 239 1510811
2002 Oblimersen Bcl-2 antisense: facilitating apoptosis in anticancer treatment. Antisense & nucleic acid drug development 223 12162702
1991 Bcl-2 maintains B cell memory. Nature 218 1908951
2011 Apoptosis and oncogenesis: give and take in the BCL-2 family. Current opinion in genetics & development 215 21236661
2009 Bcl-2 family on guard at the ER. American journal of physiology. Cell physiology 211 19279228
2012 Targeting the Bcl-2 family for cancer therapy. Expert opinion on therapeutic targets 209 23173842
2011 Mitochondrial BCL-2 inhibits AMBRA1-induced autophagy. The EMBO journal 205 21358617
2003 Control of Bcl-2 expression by reactive oxygen species. Proceedings of the National Academy of Sciences of the United States of America 199 14657380
1991 Immunolocalization of the Bcl-2 protein within hematopoietic neoplasms. Blood 192 1868240
2012 The secrets of the Bcl-2 family. Cell death and differentiation 186 22935609
2015 Discoveries and controversies in BCL-2 protein-mediated apoptosis. The FEBS journal 184 26411300
2013 Decoding and unlocking the BCL-2 dependency of cancer cells. Nature reviews. Cancer 184 23783119
1988 Oncogenic potential of bcl-2 demonstrated by gene transfer. Nature 184 2848196
2021 Targeting BCL-2 in Cancer: Advances, Challenges, and Perspectives. Cancers 173 33799470
2018 BCL-2 as therapeutic target for hematological malignancies. Journal of hematology & oncology 165 29747654
1998 Mechanisms controlling cellular suicide: role of Bcl-2 and caspases. Cellular and molecular life sciences : CMLS 154 9645223
1992 Bcl-2: an antidote to programmed cell death. Cancer surveys 148 1451107
2003 BCL-2 in prostate cancer: a minireview. Apoptosis : an international journal on programmed cell death 145 12510149
2001 Dysregulation of Reelin and Bcl-2 proteins in autistic cerebellum. Journal of autism and developmental disorders 145 11814262
1997 Bcl-2 modulates telomerase activity. The Journal of biological chemistry 143 9162048
2001 Bcl-2 is an apoptotic target suppressed by both c-Myc and E2F-1. Oncogene 142 11704823
2016 Bcl-2 proteins and calcium signaling: complexity beneath the surface. Oncogene 141 26973249
2018 BCL-2 inhibition in AML: an unexpected bonus? Blood 140 30037885
1998 Bcl-2 prevents caspase-independent cell death. The Journal of biological chemistry 140 9852091
2003 NF- kappa B2/p100 induces Bcl-2 expression. Leukemia 134 12835724
2001 Unwinding the loop of Bcl-2 phosphorylation. Leukemia 130 11417471
1995 The bcl-2 gene family. Seminars in cancer biology 128 7548840
1995 bcl-2, a novel regulator of cell death. BioEssays : news and reviews in molecular, cellular and developmental biology 125 7646485
2015 Emerging understanding of Bcl-2 biology: Implications for neoplastic progression and treatment. Biochimica et biophysica acta 122 25827952
1994 bcl-2 expression in epidermal keratinocytic diseases. Cancer 117 8082073
2002 Effect of Bcl-2 overexpression on mitochondrial structure and function. The Journal of biological chemistry 113 12207028
1998 The Bcl-2 family and cell death regulation. Current opinion in genetics & development 111 9529608
2004 Bcl-2 family members and disease. Biochimica et biophysica acta 104 14996501
2020 Therapeutic development and current uses of BCL-2 inhibition. Hematology. American Society of Hematology. Education Program 100 33275682
1998 BCL-2 promotes migration and invasiveness of human glioma cells. FEBS letters 94 9872414
2002 Endoplasmic reticulum, Bcl-2 and Ca2+ handling in apoptosis. Cell calcium 92 12543100
1996 bcl-2 protein is increased in the brain from parkinsonian patients. Neuroscience letters 92 8888015
1998 The Bcl-2 gene family and apoptosis. Advances in biochemical engineering/biotechnology 91 9755641
2020 Venetoclax causes metabolic reprogramming independent of BCL-2 inhibition. Cell death & disease 88 32792521
2005 Bcl-2 expression predicts radiotherapy failure in laryngeal cancer. British journal of cancer 87 15928664
1996 Overexpression of Bcl-2 or Bcl-XL transgenes and photoreceptor degeneration. Investigative ophthalmology & visual science 85 8933760
2020 Noncanonical Cell Fate Regulation by Bcl-2 Proteins. Trends in cell biology 84 32307222
2002 bcl-2 overexpression promotes myocyte proliferation. Proceedings of the National Academy of Sciences of the United States of America 84 11983915
1994 Analysis of the role of bcl-2 in apoptosis. Immunological reviews 83 7698791
1997 Bcl-2 inhibits p53 nuclear import following DNA damage. Oncogene 81 9419967
1994 bcl-2 in cancer, development and apoptosis. Journal of cell science. Supplement 78 7883792
2012 Multipolar functions of BCL-2 proteins link energetics to apoptosis. Trends in cell biology 75 22560661
2006 Larger than life: Mitochondria and the Bcl-2 family. Leukemia research 75 16911824
2017 Degradation of Bcl-2 by XIAP and ARTS Promotes Apoptosis. Cell reports 74 29020630
2004 Regulation of Bcl-2 proteins during anoikis and amorphosis. Biochimica et biophysica acta 74 15246684
2010 Intrinsically disordered proteins in bcl-2 regulated apoptosis. International journal of molecular sciences 65 20480043
2016 Bcl-2 inhibitors reduce steroid-insensitive airway inflammation. The Journal of allergy and clinical immunology 64 28043871
2004 Control of proliferation by Bcl-2 family members. Biochimica et biophysica acta 64 14996500
2002 Bax, Bcl-2, and p53 expression in endometrial cancer. Gynecologic oncology 63 12217750
1992 The bcl-2 oncogene and apoptosis. Seminars in immunology 63 1286168
1998 Mechanisms of Bcl-2 protein function. Histology and histopathology 62 9589906
1998 Cytoprotection by Bcl-2 requires the pore-forming alpha5 and alpha6 helices. The Journal of biological chemistry 61 9812996
2017 BCL-2: Long and winding path from discovery to therapeutic target. Biochemical and biophysical research communications 60 28212732
2017 Targeting BCL-2 in B-cell lymphomas. Blood 60 28724540
2016 Bcl-2 is a critical mediator of intestinal transformation. Nature communications 60 26956214
2014 Bcl-2 binds to and inhibits ryanodine receptors. Journal of cell science 60 24762814
1997 Upregulation of Bcl-2 and elevation of ceramide in Batten disease. Neuropediatrics 59 9151319
1994 Immunohistochemical expression of BCL-2 in melanomas and intradermal nevi. Journal of cutaneous pathology 57 7868749
2021 VDAC2 and the BCL-2 family of proteins. Biochemical Society transactions 56 34913469
2017 Therapeutics targeting Bcl-2 in hematological malignancies. The Biochemical journal 56 29061914
2009 Targeting the Bcl-2. Current opinion in oncology 56 19730103
1996 BCL-2, a novel regulator of apoptosis. Journal of cellular biochemistry 55 8825410
2008 Expression and function of bcl-2 proteins in melanoma. Current genomics 54 19506730
2004 Immunogenicity of Bcl-2 in patients with cancer. Blood 53 15367432
2016 Hematologic malignancies: newer strategies to counter the BCL-2 protein. Journal of cancer research and clinical oncology 52 27043233
1997 The bcl-2 family of proteins. British medical bulletin 52 9374031
2012 Bcl-2 inhibitors: emerging drugs in cancer therapy. Current medicinal chemistry 50 22414090

Missed literature

Know a paper Affinage missed for BCL2? Flag it for the maintainers and the community.

No submissions yet.